Triazolam and Revlimid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Triazolam and Revlimid. Common interactions include adverse drug reaction among females and haemoglobin decreased among males.

The phase IV clinical study analyzes what interactions people who take Triazolam and Revlimid have. It is created by eHealthMe based on reports of 53 people who take Triazolam and Revlimid from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

53 people who take Triazolam and Revlimid together, and have interactions are studied.


What is Triazolam?

Triazolam has active ingredients of triazolam. It is often used in insomnia. eHealthMe is studying from 5,006 Triazolam users for its effectiveness, alternative drugs and more.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 281,512 Revlimid users for its effectiveness, alternative drugs and more.

Number of Triazolam and Revlimid reports submitted per year:

Triazolam and Revlimid drug interactions.

Common Triazolam and Revlimid drug interactions by gender *:

female:

  1. Adverse drug reaction
  2. Diarrhoea
  3. Fatigue
  4. Pruritus
  5. Swelling
  6. Alopecia
  7. Full blood count decreased
  8. Gastrointestinal haemorrhage
  9. Muscle spasms
  10. Nasopharyngitis

male:

  1. Haemoglobin decreased
  2. Pulmonary embolism
  3. Dehydration
  4. Diverticulitis
  5. Drug ineffective
  6. Influenza
  7. Pneumonia
  8. Vomiting
  9. Fatigue
  10. Haemoptysis

Common Triazolam and Revlimid drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Pulmonary embolism
  2. Arthralgia
  3. Haemoptysis
  4. Death
  5. Anxiety
  6. Cholecystitis
  7. Cholelithiasis
  8. Cyanosis
  9. Deep vein thrombosis
  10. Dyspnoea

60+:

  1. Adverse drug reaction
  2. Pruritus
  3. Drug ineffective
  4. Dyspnoea
  5. Full blood count decreased
  6. Gastrointestinal haemorrhage
  7. Haemoglobin decreased
  8. Pneumonia
  9. Urinary tract infection
  10. Vomiting

Common conditions people have *:

  1. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 7 people, 13.21%

* Approximation only. Some reports may have incomplete information.

Do you take Triazolam and Revlimid?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Triazolam and Revlimid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Triazolam interactions:

Browse all interactions between Triazolam and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Revlimid interactions:

Browse all interactions between Revlimid and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on triazolam and lenalidomide (the active ingredients of Triazolam and Revlimid, respectively), and Triazolam and Revlimid (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Triazolam and Revlimid.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: